# The effects of protein kinase C epsilon peptide inhibitor (YT-001) in warm murine kidney ischemia-reperfusion

> **NIH NIH R43** · YOUNG THERAPEUTICS, LLC · 2020 · $51,000

## Abstract

PROJECT SUMMARY
The goal of the project is to test the efficacy of a protein kinase C epsilon peptide inhibitor (YT-001) in kidney
ischemia reperfusion (I/R) in vivo (in mice) when given at the beginning of reperfusion. Injury and tissue
damage associated with I/R in the kidney is a well-recognized phenomenon notably post kidney transplant.
There are 20,000 kidney transplants per year in the US and twenty five percent of transplant recipients
experience delayed graft function (DGF) within one week, a direct consequence of I/R. Currently, the only
treatment for DGF is palliative support by managing fluid and electrolyte levels via dialysis; however, these
measures provide only palliative care. Dr. Young has shown several cardiac I/R models both in-vivo and ex-
vivo that giving YT-001 at the beginning of reperfusion restores organ function and reduces cell death. The
FDA has recognized that the exact same mechanisms are at play in DGF. Phase 1 project is planned to study
the effect of YT-001 in a murine bilateral kidney I/R model to different lengths of ischemia, and reperfusion will
be carried out up to four days. During this time, serum plasma creatinine will be monitored as an index for
kidney function. This proposed methodology best mimics the settings of I/R injury seen in DGF patients.
Monitoring the role of YT-001 is crucial in the drug development process for treatment of DGF in post renal
transplant patients. After phase 1, we can begin testing the effects of YT-001 in Phase 2 (murine kidney
transplant model), which will support an IND and subsequent clinical trials.

## Key facts

- **NIH application ID:** 10087230
- **Project number:** 3R43DK121626-01A1S1
- **Recipient organization:** YOUNG THERAPEUTICS, LLC
- **Principal Investigator:** Lindon H Young
- **Activity code:** R43 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $51,000
- **Award type:** 3
- **Project period:** 2020-07-07 → 2022-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10087230

## Citation

> US National Institutes of Health, RePORTER application 10087230, The effects of protein kinase C epsilon peptide inhibitor (YT-001) in warm murine kidney ischemia-reperfusion (3R43DK121626-01A1S1). Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/grant/nih/10087230. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*